メニュー

受付時間：月〜水・金＝9時〜17時／木・土＝9時〜13時
自由診療・完全予約制TEL：092-282-7696

E-mail
  1. ホーム
  2. ネオアンチゲンペプチド樹状細胞ワクチン療法に関する論文

ネオアンチゲンペプチド樹状細胞ワクチン療法に関する論文

中　文
한국어
日本語

中　文

Neoantigen Peptide-puls Dendritic Cell Vaccine for prevention and treatment of cancer 

福冈癌症综合诊所于2019年研制出了Neoantigen肽脉冲树突状细胞疫苗，目前已将其结果发表在以下英文论文中。这是目前所有免疫疗法中最安全、最科学的疫苗疗法。 

 Publication List 
  1. Takafumi Morisaki et al.
    Retrospective analysis of HLA class-II restricted neoantigen peptide-pulsed dendritic cell vaccine for breast cancer.
    Cancers 2024,16, 4204.
    目前，全球有许多基于新抗原预测的个性化癌症疫苗疗法临床试验（顺便提一下，截至 2025 年 2 月，日本的临床试验为零）。 其中许多新抗原都是基于对癌细胞表面 HLA I 类分子亲和力的预测（即由被称为 CTL 的特化 T 淋巴细胞靶向的癌细胞表面抗原），这些抗原需要辅助 T 淋巴细胞和被其激活的树突状细胞才能在体内长期发挥作用 这就需要 HLA 二类亲和性新抗原反应 T 淋巴细胞。 本文在世界上首次发表了 II 类亲和性新抗原疫苗对预防乳腺癌术后复发的免疫学效应。
  2. Morisaki S, et al.
    Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
    Frontiers in Immunology: 14:1223331 2023
    本文报告了含有 II 类新抗原（包括治疗性 I 类新抗原）的混合新抗原树突状细胞疫苗对 IV 期结直肠癌、食道癌、卵巢癌和肉瘤患者的临床和免疫学效果及机制。
  3. Morisaki T et al.
    Lymph Nodes as anti-tumor immunotherapeutic tools: intranodal-tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy
    Cancers 2022 14, 2438
  4. Morisaki Takafumi et al.
    Neoantigens elicit T cell responses in breast cancer
    Scientific Reports 2021, 11:13590
  5. Ichimiya S et al.
    Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma
    Immunological Investigations. 2022 Vol 51, No5, 1498-1514.
  6. Morisaki T et al.
    Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients with advanced solid tumors: a retrospective analysis
    AntiCancer Research. 2021, 41:4101-4115.
  7. Morisaki T, et al.
    Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Immunol Invest. 2020 Jul 13:1-18. doi: 10.1080/08820139.2020.1778721.

福冈癌症综合诊所 森崎隆
Fukuoka General Cancer Clinic Takashi Morisaki, M.D, Ph.D.

한국어

Neoantigen Peptide-puls Dendritic Cell Vaccine for prevention and treatment of cancer

후쿠오카 암종합클리닉에서는 2019년부터 Neoantigen Peptide-puls Dendritic Cell Vaccine을 시작하였으며, 지금까지 그 성과를 아래와 같은 영문 논문으로 발표하였습니다.
안전성이 높고, 면역요법 중 가장 과학적인 근거에 기반한 백신요법입니다.

 Publication List 
  1. Takafumi Morisaki et al.
    Retrospective analysis of HLA class-II restricted neoantigen peptide-pulsed dendritic cell vaccine for breast cancer.
    Cancers 2024,16, 4204.
    현재 세계적으로 신항암제 예측에 근거한 개별화 암 백신 치료의 임상시험이 다수 진행되고 있다(참고로 일본은 2025년 2월 현재 제로). 그 중 대부분은 암세포 표면의 HLA-클래스 I 분자에 친화성이 있는 네오항원(즉, CTL이라고 불리는 특수 T림프구가 표적으로 하는 암세포 표면 항원)의 예측에 기초하고 있다. CTL이 체내에서 장기적으로 기능하려면 헬퍼 T림프구와 그로 인해 활성화되는 수지상 세포가 필요하지만, 이를 위해서는 HLA-클래스 II 친화성 네오항원 반응성 T림프구가 필요하다. 본 논문은 유방암 수술 후 재발 방지를 목적으로 한 클래스 II 친화성 네오항원 백신에 의한 면역학적 효과를 세계 최초로 발표했다.
  2. Morisaki S, et al.
    Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
    Frontiers in Immunology: 14:1223331 2023
    본 논문에서는 4기 대장암, 식도암, 난소암, 육종 환자를 대상으로 치료적으로 클래스 I 네오항원을 포함한 클래스 II 네오항원에 의한 하이브리드 네오항원 수지상세포 백신의 임상적 효과와 면역학적 효과 및 그 메커니즘에 대해 보고하였다.
  3. Morisaki T et al.
    Lymph Nodes as anti-tumor immunotherapeutic tools: intranodal-tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy
    Cancers 2022 14, 2438
  4. Morisaki Takafumi et al.
    Neoantigens elicit T cell responses in breast cancer
    Scientific Reports 2021, 11:13590
  5. Ichimiya S et al.
    Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma
    Immunological Investigations. 2022 Vol 51, No5, 1498-1514.
  6. Morisaki T et al.
    Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients with advanced solid tumors: a retrospective analysis
    AntiCancer Research. 2021, 41:4101-4115.
  7. Morisaki T, et al.
    Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Immunol Invest. 2020 Jul 13:1-18. doi: 10.1080/08820139.2020.1778721.

후쿠오카 암 종합 클리닉 모리사키 타카시
Fukuoka General Cancer Clinic Takashi Morisaki, M.D, Ph.D.

日本語

ネオアンチゲン樹状細胞ワクチン療法

福岡総合がんクリニックは、2019年よりネオアンチゲンペプチドパルス樹状細胞ワクチンを開発し、これまでその成果を以下の英文論文で発表しています。このがんワクチン療法は、現在利用可能な免疫療法の中で最も安全で科学的に証明されたがんの再発予防、治療法の一つです。

これまで発表した本治療に関する医学英文
  1. Takafumi Morisaki et al.
    Retrospective analysis of HLA class-II restricted neoantigen peptide-pulsed dendritic cell vaccine for breast cancer.
    Cancers 2024,16, 4204.
    現在、世界的にはネオアンチゲンの予測に基づく個別化がんワクチン療法の臨床試験が数多く行われている（ちなみに日本は2025年2月時点でゼロ）。その多くは、がん細胞表面のHLA-クラスI分子に親和性のあるネオアンチゲン（つまり、CTLといわれる特殊なTリンパ球が標的とするがん細胞表面抗原）の予測に基づいている。CTLが体内で長期的に機能するにはヘルパーTリンパ球とそれにより活性化される樹状細胞が必要だが、そのためにはHLA-クラスII親和性ネオアンチゲン反応性Tリンパ球が必要である。本論文は、乳癌術後再発予防を目的としたクラスII親和性ネオアンチゲンワクチンによる免疫学的効果を世界に先駆けて発表した。
  2. Morisaki S, et al.
    Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
    Frontiers in Immunology: 14:1223331 2023
    本論文では、ステージIVの大腸がん、食道がん、卵巣がん、肉腫の患者に対して、治療的にクラスIネオアンチゲンを含むクラスIIネオアンチゲンによるハイブリッドネオアンチゲン樹状細胞ワクチンの臨床効果と免疫学的効果とそのメカニズムについて報告した。
  3. Morisaki T et al.
    Lymph Nodes as anti-tumor immunotherapeutic tools: intranodal-tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy
    Cancers 2022 14, 2438
  4. Morisaki Takafumi et al.
    Neoantigens elicit T cell responses in breast cancer
    Scientific Reports 2021, 11:13590
  5. Ichimiya S et al.
    Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma
    Immunological Investigations. 2022 Vol 51, No5, 1498-1514.
  6. Morisaki T et al.
    Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients with advanced solid tumors: a retrospective analysis
    AntiCancer Research. 2021, 41:4101-4115.
  7. Morisaki T, et al.
    Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Immunol Invest. 2020 Jul 13:1-18. doi: 10.1080/08820139.2020.1778721.